Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 10 od 41  
Back povratak na rezultate
2015, vol. 68, br. 9-10, str. 324-330
Kompletna korekcija anemije Rekormonom® (Eritropoetin β) kod bolesnika na hroničnom programu hemodijalize
aUniverzitet u Beogradu, Medicinski fakultet + Kliničko-bolnički centar Zvezdara, Beograd
bUniverzitet u Novom Sadu, Medicinski fakultet + Klinički centar Vojvodine, Klinika za nefrologiju i kliničku imunologiju, Novi Sad
cMedical Center, Kruševac
dMedical Center, Pirot
eGeneral Hospital 'Djordje Joanović', Zrenjanin
fUniverzitet u Beogradu, Medicinski fakultet, Institut za medicinsku statistiku i informatiku

e-adresadim@eunet.rs
Sažetak
Uvod. Suboptimalna korekcija anemije udružena je sa povećanom prevalencijom kardiovaskularnih bolesti i povećanim morbiditetom i mortalitetom bolesnika na dijalizi. Cilj ove studije bio je da se uporedi efekat optimalne u odnosu na suboptimalnu korekciju anemije kod bolesnika na hemodijalizi koji imaju hipertrofiju leve komore. Materijal i metode. U ovu multicentričnu studiju u trajanju od 12 meseci uključeno je 50 bolesnika (32 muškaraca, prosečna starost 49,4±11,8 godina) iz pet centara za hemodijalizu (Kliničko bolnički centar Zvezdara, Beograd, Klinički centar Novi Sad, bolnice u Kruševcu, Pirotu i Zrenjaninu). Bolesnici su i pored terapije imali suboptimalne vrednosti hemoglobina (7,8±3,8 g/dl) i indeks mase leve komore preko 160 g/m2. Primarni parametar efikasnosti bio je smanjenje indeksa mase leve komore tokom studijskog perioda od 12 meseci. Rezultati. Tokom trajanja studije povećan je broj bolesnika sa hemoglobinom > 12 g/dl i na kraju ciljne vrednosti hemoglobina (12-13 g/dl) postignute su kod 24 (52%) bolesnika. Vrednosti indeksa mase leve komore značajno su se smanjile u odnosu na početne vrednosti (p = 0,014). Indeks mase leve komore nije značajno smanjen kod bolesnika koji nisu dostigli ciljne vrednosti hemoglobina (207±65 vs. 217±38 g, p = ns) u odnosu na bolesnike koji su postigli ciljne vrednosti hemoglobina (179±32 g/m2 vs. 197±38 g/m2, p = 0,007). Ejekciona frakcija leve komore nije se značajno menjala tokom trajanja studije. Zaključak. Korekcija anemije primenom eritropoetina β dovela je do značajne korekcije hipertrofije leve komore kod bolesnika koji su prethodno imali suboptimalne vrednosti hemoglobina. Naši rezultati pokazuju da je za ovaj efekat potrebna korekcija hemoglobina do vrednosti od najmanje 12 g/dl.
Reference
Akaishi, M., Hiroe, M., Hada, Y., Suzuki, M., Tsubakihara, Y., Akizawa, T. (2013) Effect of anemia correction to the modestly high hemoglobin level in patients with chronic kidney disease on left ventricular hypertrophy. Journal of Cardiology, 62(4): 249-256
Astor, B.C., Coresh, J., Heiss, G., Pettitt, D., Sarnak, M.J. (2006) Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J, 151(2): 492-500
Ayus, J.C., Go, A.S., Valderrabano, F., Verde, E., de Vinuesa, S.G., Achinger, S.G., Lorenzo, V., Arieff, A.I., Luño, J. (2005) Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int, 68(2): 788-95
Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., Schwab, S.J., Goodkin, D.A. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med, 339(9): 584-90
Eckardt, K.-U., Scherhag, A., Macdougall, I.C., Tsakiris, D., Clyne, N., Locatelli, F., Zaug, M.F., Burger, H.U., Drueke, T.B. (2009) Left Ventricular Geometry Predicts Cardiovascular Outcomes Associated with Anemia Correction in CKD. Journal of the American Society of Nephrology, 20(12): 2651-2660
Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W. (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med, 316(2): 73-8
Eschbach, J.W., Adamson, J.W. (1985) Anemia of end-stage renal disease (ESRD). Kidney Int, 28(1): 1-5
Foley, R.N. (2002) Anaemia: cardiovascular adaptations and maladaptive responses in chronic kidney disease. Nephrol Dial Transplant, 17(11): 32-34, suppl
Foley, R.N., Parfrey, P.S., Harnett, J.D., Kent, G.M., Murray, D.C., Barre, P.E. (1996) The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis, 28(1): 53-61
Ishani, A., Solid, C.A., Weinhandl, E.D., Gilbertson, D.T., Foley, R.N., Collins, A.J. (2008) Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrology Dialysis Transplantation, 23(5): 1682-1689
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int, (2): 279-335, suppl
Knežević, V. (2008) The effect of recombinant human erythropoietin on left ventricular hypertrophy in hemodialysis patients. Novi Sad: School of Medicine, thesis
Leeder, S.R., Mitchell, P., Liew, G., Rochtchina, E., Smith, W., Wang, J.J. (2006) Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the Blue Mountains Eye Study. J Am Soc Nephrol, 17(1): 279-84
Locatelli, F. (2003) Effect of anaemia on left ventricular hypertrophy in end-stage renal disease. European Journal of Heart Failure Supplements, 2(2): 207-212
Molnar, M.Z., Mehrotra, R., Duong, U., Kovesdy, C.P., Kalantar-Zadeh, K. (2011) Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol, 6(8): 1973-81
Owen, W.F., Madore, F., Brenner, B.M. (1996) An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors. Am J Kidney Dis, 28(6): 931-6
Pappas, K.D., Gouva, C.D., Katopodis, K.P., Nikolopoulos, P.M., Korantzopoulos, P.G., Michalis, L.K., Goudevenos, J.A., Siamopoulos, K.C. (2008) Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther, 22(1): 37-44
Parfrey, P.S., Foley, R.N., Harnett, J.D., Kent, G.M., Murray, D., Barre, P.E. (1996) Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int, 49(5): 1428-34
Parfrey, P.S., Lauve, M., Latremouille-Viau, D., Lefebvre, P. (2009) Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol, 4(4): 755-62
Pascual, J., Teruel, J.L., Moya, J.L., Liaño, F., Jiménez-Mena, M., Ortuño, J. (1991) Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol, 35(6): 280-7
Petrović, D., Stojimirović, B. (2008) Cardiovascular morbidity and mortality in patients treated with hemodialysis: Epidemiological analysis. Vojnosanitetski pregled, vol. 65, br. 12, str. 893-900
Pfeffer, M.A., Burdmann, E.A., Chen, C., Cooper, M.E., de Zeeuw, D., Eckardt, K., Feyzi, J.M., Ivanovich, P., Kewalramani, R., Levey, A.S., Lewis, E.F., McGill, J.B., McMurray, J.J.V., Parfrey, P. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med, 361(21): 2019-32
Ritz, E., Zeier, M., Schneider, P., Jones, E. (1994) Cardiovascular mortality of patients with polycystic kidney disease on dialysis: Is there a lesson to learn?. Nephron, 66(2): 125-8
Shiba, N., Shimokawa, H. (2011) Chronic kidney disease and heart failure—Bidirectional close link and common therapeutic goal. Journal of Cardiology, 57(1): 8-17
Silberberg, J.S., Barre, P.E., Prichard, S.S., Sniderman, A.D. (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int, 36(2): 286-90
Silverberg, D.S., Wexler, D., Blum, M., Tchebiner, J.Z., Sheps, D., Keren, G., Schwartz, D., Baruch, R., Yachnin, T., Shaked, M., Schwartz, I., Steinbruch, S., Iaina, A. (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant, 18(1): 141-6
Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M., Reddan, D. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine, 355(20): 2085-98
Sood, M.M., Pauly, R.P., Rigatto, C., Komenda, P. (2008) Left ventricular dysfunction in the haemodialysis population. NDT Plus, 1(4): 199-205
Stojimirović, B., Petrović, D., Obrenović, R. (2007) Left ventricular hypertrophy in hemodialysis patients: importance of anemia. Medicinski pregled, 50(Suppl 2): 155-9
The National Kidney Foundation I (2001) Kidney-Dialysis Outcome Quality Initiative: K/DOQI Clinical Practice Guidelines: Anemia of chronic kidney disease. Am J Kidney Dis, 37(1): 182-283
Vlagopoulos, P.T., Tighiouart, H., Weiner, D.E., Griffith, J., Pettitt, D., Salem, D.N., Levey, A.S., Sarnak, M.J. (2005) Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. Journal of the American Society of Nephrology, 16(11): 3403-10
Weiner, D.E., Tighiouart, H., Vlagopoulos, P.T., Griffith, J.L., Salem, D.N., Levey, A.S., Sarnak, M.J. (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol, 16(6): 1803-10
Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M. (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 2(8517): 1175-8
Wizemann, V., Kaufmann, J., Kramer, W. (1992) Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron, 62(2): 161-5
Wizemann, V., Schäfer, R., Kramer, W. (1993) Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron, 64(2): 202-6
Zehnder, C., Zuber, M., Sulzer, M., Meyer, B., Straumann, E., Jenzer, H.R., Blumberg, A. (1992) Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron, 61(1): 21-5
Zoccali, C., Benedetto, F.A., Tripepi, G., Mallamaci, F., Rapisarda, F., Seminara, G., Bonanno, G., Malatino, L.S. (2006) Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol, 17(5): 1460-5
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/mpns1510324d
objavljen u SCIndeksu: 25.10.2015.